Regeneron Pharmaceuticals, Inc. (REGN)
| Market Cap | 60.47B |
| Revenue (ttm) | 14.21B |
| Net Income (ttm) | 4.46B |
| Shares Out | 103.69M |
| EPS (ttm) | 39.67 |
| PE Ratio | 14.70 |
| Forward PE | 14.92 |
| Dividend | $3.52 (0.60%) |
| Ex-Dividend Date | Aug 18, 2025 |
| Volume | 656,274 |
| Open | 587.59 |
| Previous Close | 585.48 |
| Day's Range | 578.42 - 591.45 |
| 52-Week Range | 476.49 - 1,024.36 |
| Beta | 0.31 |
| Analysts | Buy |
| Price Target | 794.83 (+36.28%) |
| Earnings Date | Oct 28, 2025 |
About REGN
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company’s products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous sq... [Read more]
Financial Performance
In 2024, Regeneron Pharmaceuticals's revenue was $14.20 billion, an increase of 8.27% compared to the previous year's $13.12 billion. Earnings were $4.41 billion, an increase of 11.61%.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for REGN stock is "Buy." The 12-month stock price target is $794.83, which is an increase of 36.28% from the latest price.
News
11 Cheap Stocks for a Market That's Too Expensive
Amid a pricey market, Evercore wanted to find stocks that are less pricey but have staying power. Here's how they did it and what they found.
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
Regeneron: Growth Catalysts Incoming
Regeneron Pharmaceuticals, Inc. is rated a Buy, supported by strong Dupixent and oncology growth offsetting Eylea/Eylea HD declines. REGN's robust pipeline, best-in-class products, and upcoming patent...
Regeneron to Report Third Quarter 2025 Financial and Operating Results and Host Conference Call and Webcast on October 28, 2025
TARRYTOWN, N.Y., Sept. 30, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its third quarter 2025 financial and operating results on Tuesday...
Final Trades: Nvidia, Amphenol, Regeneron and Lockheed Martin
CNBC's "Halftime Report" team detail their stock picks and final trades.
Regeneron: Strong R&D Pipeline Drives Growth Outlook
Retail investors' fears over the launch of Eylea biosimilars are gradually fading amid the strong performance of Dupixent and Libtayo, actively gaining share in the PD-1 and PD-L1 inhibitors market. S...
Evkeeza® (evinacumab-dgnb) ANGPTL3 Antibody Approved in the U.S. for Children as Young as 1 Year Old with Ultra-Rare Form of High Cholesterol
FDA approval extends the indication of Evkeeza to treat younger patients with homozygous hypercholesterolemia (HoFH) HoFH is an inherited condition characterized by extremely high levels of low-densit...
Regeneron Pharmaceuticals, Inc. (REGN) Presents at Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Bernstein Insights: Healthcare Leaders and Disruptors - 2nd Annual Healthcare Forum September 24, 2025 10:30 AM EDT Company Participants Ryan Crowe - Sen...
Regeneron: Looking For Green Shoots Of Growth On Top Of Heartwood Franchises
Regeneron Pharmaceuticals remains a top conviction idea, driven by strong Dupixent growth, a robust pipeline, and a healthy balance sheet. REGN's Q2 earnings showed solid revenue and EPS growth, with ...
Press Release: Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion
Sanofi and Regeneron's Dupixent to treat chronic spontaneous urticaria advances in EU with positive CHMP opinion Recommendation for adults and adolescents based on phase 3 studies showing Dupixent sig...
Dupixent® (dupilumab) to Treat Chronic Spontaneous Urticaria (CSU) Advances in EU with Positive CHMP Opinion
Recommendation for adults and adolescents based on Phase 3 trials showing Dupixent significantly reduced itch and hives at 24 weeks compared to placebo
Regeneron says blood cancer therapy shows 100% response rate in precancerous disorder study
Regeneron said on Friday its experimental therapy showed either a complete or partial disappearance of a precancerous disorder, which manifests into blood cancer, in all patients in a mid-stage trial.
Regeneron Donates Ebola Treatment for Use in Countries Most at Risk of Outbreaks
Inmazeb ® (atoltivimab, maftivimab, and odesivimab-ebgn) was the first treatment approved by the U.S. Food and Drug Administration (FDA) for Orthoebolavirus zairense , also known as Zaire ebolavirus
Regeneron's bone disorder treatment succeeds in late-stage trial
Regeneron Pharmaceuticals said on Wednesday its experimental treatment for a rare genetic disorder that affects bone tissue has met the main goal of a late-stage trial.
Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation
FOP is a disease in which muscles, tendons and ligaments are progressively replaced by bone, leading to eventual incapacitation
Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer
Late-breaking data from exploratory analyses at WCLC show Libtayo plus chemotherapy demonstrates a more than double five-year overall survival rate of 19.4%, compared to 8.8% with chemotherapy alone
Regeneron Pharmaceuticals, Inc. (REGN) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference (Transcript)
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Morgan Stanley 23rd Annual Global Healthcare Conference September 8, 2025 7:00 AM EDT Company Participants Christopher Fenimore - Executive VP of Finance...
What's Happening With Regeneron Pharmaceuticals Stock On Monday?
Regeneron Pharmaceuticals, Inc. REGN revealed data from Phase 3 trials in adults with moderate-to-severe cat or birch allergies on Monday. Both trials met their respective primary and key secondary en...
Regeneron Announces Updated Presentation Time for Upcoming Investor Conference
TARRYTOWN, N.Y., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) announced today that it will now present at the Morgan Stanley 23rd Annual Global Healthcare Conferen...
Regeneron Pharmaceuticals, Inc. (REGN) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Wells Fargo 20th Annual Healthcare Conference 2025 September 4, 2025 9:30 AM EDT Company Participants Ryan Crowe - Senior Vice President of Investor Rela...
Regeneron Pharmaceuticals, Inc. (REGN) Presents At Cantor Global Healthcare Conference 2025 (Transcript)
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Cantor Global Healthcare Conference 2025 September 3, 2025 1:35 PM EDT Company Participants Ryan Crowe - Senior Vice President of Investor Relations & St...
Regeneron: Drug Pricing Woes Notwithstanding, Due For A Major Comeback
Regeneron Pharmaceuticals, Inc. shares have lost >50% of their value over the past 12 months. Regeneron remains a powerhouse pharma however, despite threats to its key drug Eylea from generics and lon...
Final Trades: ServiceNow, Regeneron, Cisco Systems and Truist Financial
The Investment Committee give you their top stocks to watch for the second half.
Regeneron's rare immune disorder therapy meets main goal of late-stage trial
Regeneron Pharmaceuticals said on Tuesday its experimental therapy for treating patients with a rare immune disorder has met the main goal of a late-stage study.
Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis
Cemdisiran monotherapy, dosed subcutaneously every three months, met the primary and key secondary endpoints, showing a 2.3-point placebo-adjusted improvement in Myasthenia Gravis Activities of Daily ...